Regeneron Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Leonard Schleifer

Chief Executive Officer (CEO)

US$7.0m

Compensación total

Porcentaje del salario del CEO	25.9%
Permanencia del CEO	36yrs
Participación del CEO	2.3%
Permanencia media de la dirección	6.8yrs
Promedio de permanencia en la Junta Directiva	17.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Leonard Schleifer en comparación con los beneficios de Regeneron Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2023	n/a	n/a	US$4b
Jun 30 2023	n/a	n/a	US$4b
Mar 31 2023	n/a	n/a	US$4b
Dec 31 2022	US$7m	US$2m	US$4b
Sep 30 2022	n/a	n/a	US$5b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$6m	US$2m	US$8b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$135m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$21m	US$1m	US$2b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$27m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$27m	US$1m	US$1b

Compensación vs. Mercado: Leonard($USD7.00M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD4.53M).

Compensación vs. Ingresos: Leonardha sido coherente con los resultados de la empresa en el último año.

CEO

Leonard Schleifer (70 yo)

36yrs

Permanencia

US$7,004,069

Compensación

Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Leonard Schleifer	Co-Founder	36yrs	US$7.00m	2.28% $ 2.1b
George Yancopoulos	Co-Founder	23yrs	US$6.59m	1.19% $ 1.1b
Robert Landry	Executive VP of Finance & CFO	10.3yrs	US$8.84m	0.022% $ 19.7m
Andrew Murphy	Executive Vice President of Research	5yrs	US$9.12m	0.049% $ 45.4m
Daniel Van Plew	Executive VP and GM of Industrial Operations & Product Supply	15.8yrs	US$8.85m	0.032% $ 29.2m
Marion McCourt	Executive Vice President of Commercial	5.9yrs	US$6.90m	0.014% $ 13.1m
Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	4yrs	sin datos	sin datos
Christopher Fenimore	Senior VP	6.8yrs	sin datos	0.025% $ 23.2m
Gerald Underwood	Senior Vice President of Technical Operations	4yrs	sin datos	sin datos
Bob McCowan	Senior VP of IT & Chief Information Officer	3yrs	sin datos	sin datos
Ryan Crowe	Vice President of Investor Relations	no data	sin datos	sin datos
Joseph LaRosa	Executive VP	12.3yrs	US$7.13m	0.041% $ 37.3m

6.8yrs

Permanencia media

63yo

Promedio de edad

Equipo directivo experimentado: RGOEl equipo directivo de la empresa es veterano y experimentado (6.8 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Leonard Schleifer	Co-Founder	36yrs	US$7.00m	2.28% $ 2.1b
George Yancopoulos	Co-Founder	23yrs	US$6.59m	1.19% $ 1.1b
Christine Poon	Lead Independent Director	13.2yrs	US$720.03k	0.00074% $ 678.6k
Arthur Ryan	Independent Director	21yrs	US$725.03k	0.017% $ 15.9m
Michael Brown	Independent Director	32.6yrs	US$725.03k	0.012% $ 10.8m
Joseph Goldstein	Independent Director	32.6yrs	US$710.03k	0.0047% $ 4.3m
George Sing	Independent Director	36yrs	US$720.03k	0.027% $ 24.6m
N. Coles	Independent Director	7yrs	US$705.03k	0.000010% $ 9.2k
Craig Thompson	Independent Director	1.3yrs	US$1.02m	0.00043% $ 394.3k
Huda Zoghbi	Independent Director	7.3yrs	US$715.03k	0% $ 0
Bonnie Bassler	Independent Director	7.3yrs	US$715.03k	0% $ 0
Kathryn Guarini	Independent Director	less than a year	sin datos	sin datos

17.1yrs

Permanencia media

70yo

Promedio de edad

Junta con experiencia: RGOLos consejos de administración de la empresa son veteranos y experimentados ( 17 años de permanencia media en el cargo).

Regeneron Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Recent updates

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Announces Clinical Data from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad